Monte Rosa Therapeutics
GLUE
116 hedge funds and large institutions have $281M invested in Monte Rosa Therapeutics in 2025 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 50 increasing their positions, 17 reducing their positions, and 17 closing their positions.
1,510% more call options, than puts
Call options by funds: $483K | Put options by funds: $30K
194% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 17
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
10% more funds holding
Funds holding: 105 → 116 (+11)
4.37% more ownership
Funds ownership: 96.77% → 101.14% (+4.4%)
2% more capital invested
Capital invested by funds: $276M → $281M (+$4.38M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$8.01M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$4.7M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.08M |
| 4 |
Renaissance Technologies
New York
|
+$2.01M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.6M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$4.11M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.42M |
| 4 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
-$1.33M |
| 5 |
Millennium Management
New York
|
-$1.19M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ETC
126
Exchange Traded Concepts
Oklahoma City,
Oklahoma
| – | -$87.8K | -18,928 | Closed |
|
|
TC
127
TownSquare Capital
Provo,
Utah
| – | -$52.9K | -11,391 | Closed |
|
128
Simplex Trading
Chicago,
Illinois
| – | -$30.1K | -6,756 | Closed |
|
129
Group One Trading
Chicago,
Illinois
| – | -$24.1K | -5,398 | Closed |
|
|
CCM
130
Coldstream Capital Management
Bellevue,
Washington
| – | -$1.65K | -355 | Closed |
|
131
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$1.39K | -300 | Closed |
|
|
AAP
132
Arax Advisory Partners
Denver,
Colorado
| – | -$441 | -95 | Closed |
|
|
PFBT
133
Parkside Financial Bank & Trust
Saint Louis,
Missouri
| – | -$441 | -95 | Closed |
|
GLUE Hedge Fund Activity: Q2 2025 in Review
116 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q2 2025, worth a combined $281M — up 1.6% from $276M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new GLUE positions and 17 closed out — a net gain of 11 holders — while 50 added to existing stakes and 17 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $8.01M. The largest seller was Fidelity Investments, cutting an estimated $10.6M.
- 116 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q2 2025, up from 105 in Q1 2025.
- Funds reported $281M of Monte Rosa Therapeutics stock for Q2 2025, up 1.6% quarter-over-quarter.
- 28 funds opened new Monte Rosa Therapeutics positions in Q2 2025 and 17 closed out, a net change of +11 holders.
- The largest Monte Rosa Therapeutics buyer in Q2 2025 was Suvretta Capital Management, an estimated $8.01M added.
- The largest Monte Rosa Therapeutics seller in Q2 2025 was Fidelity Investments, an estimated $10.6M sold.
Based on aggregated 13F filings for Q2 2025.